TrialThe Lancet. Oncology2013

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.

Pirkko-Liisa Kellokumpu-Lehtinen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.